Semaglutide and tirzepatide (only one trial), but not liraglutide, were associated with a higher chance of restoring normoglycemia in patients with pre-existing glycemic alterations (Table 1)
Of the patients that switched, nearly half of them paid out of pocket for branded GLP-1 drugs, while the rest relied on commercial insurance to pay for branded drugs, revealing a significant cost barrier to switching
232 Voelker, B
Through August 31, 2026, pay $149/month for the two lowest doses of daily Wegovy pills through a Novo Nordisk offer, subsequent doses are up to $299/month, restrictions and exclusions apply.** Or through June 30, 2026, get your first two months of weekly Wegovy injectables for $199/month through an introductory Novo Nordisk offer, subsequent doses up to $349/month, restrictions and exclusions apply
JiangLZhangYJingFLongTQinGZhangDet al